Logo
x

Search category

Subscribe Now

Neurocrine Biosciences

Neurocrine Biosciences Reports P-III Study (CAHtalyst) Results of Crinecerfont for Congenital Adrenal Hyperplasia in Adults

Neurocrine Biosciences Reports P-III Study (CAHtalyst) Results of Crinecerfont for Congenital Adrenal Hyperplasia in Adults

  • September 13, 2023
PharmaShots Weekly Snapshots (August 21 – 25, 2023)

PharmaShots Weekly Snapshots (August 21 – 25, 2023)

  • August 25, 2023
Neurocrine Biosciences’ Ingrezza (valbenazine) Capsules Receives the US FDA’s Approval for the Treatment of Chorea Associated with Huntington's Disease

Neurocrine Biosciences’ Ingrezza (valbenazine) Capsules Receives the US FDA’s Approval for the Treatment of Chorea Associated with...

  • August 21, 2023
Neurocrine Biosciences’ Valbenazine Receives the US FDA’s Orphan Drug Designation for the Treatment of Chorea Associated with Huntington Disease

Neurocrine Biosciences’ Valbenazine Receives the US FDA’s Orphan Drug Designation for the Treatment of Chorea Associated with Hunt...

  • May 13, 2022
Neurocrine Presents New Data Analyses of Ongentys (opicapone) for Parkinson Disease at ANA 2020 Virtual Meeting

Neurocrine Presents New Data Analyses of Ongentys (opicapone) for Parkinson Disease at ANA 2020 Virtual Meeting

  • September 28, 2020
PharmaShots' Key Highlights of Second Quarter 2020

PharmaShots' Key Highlights of Second Quarter 2020

  • July 7, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.